Furthermore, DOCK2 inhibition using CPYPP significantly reduced RAC1P29S activity in a dose-dependent manner, which supports the central role of DOCK2 as the primary GEF responsible for RAC1P29S activation in melanoma cells. Here, DOCK2 is linked to melanoma.